Q3 2024 EPS Estimates for Teladoc Health, Inc. Reduced by Zacks Research (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) – Stock analysts at Zacks Research decreased their Q3 2024 EPS estimates for shares of Teladoc Health in a note issued to investors on Wednesday, August 14th. Zacks Research analyst D. Chatterjee now expects that the health services provider will earn ($0.28) per share for the quarter, down from their prior forecast of ($0.22). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.69) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($1.15) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.75) EPS.

TDOC has been the topic of a number of other reports. Evercore ISI dropped their target price on shares of Teladoc Health from $14.00 to $10.00 and set an “in-line” rating on the stock in a report on Tuesday, July 9th. TD Cowen dropped their target price on shares of Teladoc Health from $15.00 to $9.00 and set a “hold” rating on the stock in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a report on Thursday, August 1st. Barclays dropped their target price on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Teladoc Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, May 21st. Fourteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $13.56.

Teladoc Health Trading Up 0.7 %

Teladoc Health stock opened at $7.11 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The firm has a 50-day moving average of $9.09 and a 200-day moving average of $12.69. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -5.04 and a beta of 0.93. Teladoc Health has a one year low of $6.77 and a one year high of $23.59.

Institutional Trading of Teladoc Health

Large investors have recently made changes to their positions in the company. Hexagon Capital Partners LLC boosted its position in shares of Teladoc Health by 204.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock worth $34,000 after acquiring an additional 1,065 shares in the last quarter. Allianz Asset Management GmbH boosted its position in Teladoc Health by 15.4% in the fourth quarter. Allianz Asset Management GmbH now owns 604,238 shares of the health services provider’s stock valued at $13,021,000 after buying an additional 80,805 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Teladoc Health by 74.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 20,568 shares of the health services provider’s stock valued at $311,000 after buying an additional 8,750 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Teladoc Health by 188.7% in the first quarter. Janney Montgomery Scott LLC now owns 31,594 shares of the health services provider’s stock valued at $477,000 after buying an additional 20,651 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after buying an additional 1,855,480 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Transactions at Teladoc Health

In other Teladoc Health news, Director Thomas Mckinley bought 7,000 shares of the stock in a transaction dated Tuesday, August 6th. The shares were bought at an average cost of $7.57 per share, with a total value of $52,990.00. Following the completion of the acquisition, the director now owns 31,077 shares of the company’s stock, valued at $235,252.89. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Karen L. Daniel sold 9,834 shares of the stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $11.90, for a total transaction of $117,024.60. Following the sale, the director now owns 36,995 shares in the company, valued at approximately $440,240.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Mckinley purchased 7,000 shares of Teladoc Health stock in a transaction that occurred on Tuesday, August 6th. The shares were purchased at an average price of $7.57 per share, for a total transaction of $52,990.00. Following the transaction, the director now directly owns 31,077 shares in the company, valued at approximately $235,252.89. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 52,714 shares of company stock valued at $472,714. 0.95% of the stock is currently owned by company insiders.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.